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CK19Abstract Background: Well differentiated thyroid tumor of uncertain malignant potential (WDT-
UMP) represents a true ‘‘gray zone’’ of ‘‘follicular patterned’’ thyroid lesions, that needs to be
characterized in order to outright the diagnosis of carcinoma and avoid unnecessary aggressive
treatment.
Aim: To emphasize on the histomorphological criteria for more accurate diagnosis of WDT-UMP.
Also to compare the immunohistochemical expression of CK19 of WDT-UMP versus adenoma and
papillary thyroid carcinoma (PTC).
Materials and methods: The study included 60 thyroid specimens; 18 WDT-UMPs, 24 PTC (18
classic variant and 6 follicular variants) and 18 benign thyroid lesions (8 adenoma, 6
Hashimoto’s thyroiditis and 4 hyperplastic nodules). H&E stained sections were assessed according
to the published major and minor criteria of malignancy in the thyroid. CK 19 immunostaining was
examined and evaluated according to the proportion and intensity scores.
Results: We could detect the absence of nuclear inclusions, presence of characteristic nuclear
groove, nuclear clearing, ovoid nuclei, nuclear crowdness, nuclear enlargement and pleomorphism
as important reliable features for diagnosis of WDT-UMP with p value (<0.0001 for each).
WDT-UMP showed moderate to strong CK 19 immunostaining with proportion scores 3 and 4;
an intermediate expression proﬁle; higher than adenoma and less than papillary carcinoma
(p< 0.0001).
Figure 1 Nomenclature for enca
tumors; if PTC-N are equivocal, it
PTC-N are unequivocal but focal, it s
PTC-N are unequivocal but diffus
(modiﬁed from Williams’ proposal) [3
60 F.E.-Z.S.E.-D. YassinConclusion: The constellations of both major and minor criteria of malignancy are important clues
for WDT-UMP diagnosis which could be ascertained by CK 19 immunostaining.
ª 2015 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Williams, 2000 proposed a diagnostic terminology in thyroid
pathology; a well differentiated tumor of uncertain malignant
potential (WDT-UMP) for capsulated follicular pattern
tumors with diffuse equivocal or focal unequivocal papillary
thyroid carcinoma type nuclear changes (PTC-Ns) and with-
out deﬁnite invasion. This group of tumors has been suggested
to be borderline in nature [1].
PTC-type nuclear changes (PTC-Ns) are cited in the litera-
ture and textbooks as the diagnostic criteria for malignancy in
thyroid tumors, regardless of whether or not the tumor has a
capsule, is invasive, or has a papillary growth pattern [2], they
included cytoplasmic pseudo inclusions, nuclear grooves,
nuclear clearing, elongated overlapping nuclei and nuclear
irregularity [3].
When PTC-Ns were observed equivocally, such as only
nuclear clearing and nuclear grooves without nuclear pseudo
inclusions, thyroid lesions will be classiﬁed as WDT-UMP.
When unequivocal PTC-Ns were seen in the entire part of
the tumor it will be as encapsulated follicular variant papillary
thyroid carcinoma. When unequivocal PTC-Ns were found in
only part of the tumor, it will be classiﬁed as WDT-UMP, as
explained in (Fig. 1) [3].
The immunohistochemical studies have been reported as a
helpful tool in conﬁrming diagnosis of malignancy in thyroid
lesions with special reference to CK19; is one of the most
commonly used keratin to investigate thyroid lesions with high
sensitivity (92%) and speciﬁcity (97%) when used as a single
marker [4–6].psulated thyroid follicular
should be WDT-UMP, if
hould be WDT-UMP and if
e it should be EFV-PTC
].WDT-UMP is still a controversial entity among expert
pathologists [3], so the purpose of this study is to emphasize
on the histomorphological criteria for more accurate diagnosis
of WDT-UMP. Also to compare the immunohistochemical
expression of CK19 of WDT-UMP versus adenoma and
papillary thyroid carcinoma (PTC).
Material and methods
Patients and tissue samples
This was a retrospective study carried out in the Pathology
Department, Sohag University Hospital, during the period
from Jan 2011 till June 2014.
The hematoxylin and eosin (H&E) stained sections of 200
specimens of the thyroid nodules were reviewed, 60 out of
200 cases were selected and categorized into three groups
according to their ﬁnal diagnosis which was based on the
terminology of the Chernobyl Pathologist Group and modiﬁed
Williams’ proposal [1].
The ﬁrst group (n = 18)
All cases were encapsulated, follicular patterned tumors with
diffuse equivocal or focal unequivocal PTC-N features, with-
out capsular or vascular invasion and well demarcated from
the surrounding thyroid parenchyma. They were diagnosed as
WDT-UMPs.
The second group (n = 24)
They are formed of follicular patterned lesions with diffuse
unequivocal PTC-N features; diagnosed as encapsulated
follicular variant of PTC (EFV-PTC, n= 6), and 18 cases
were classic PTC. This group was considered a control group
of malignant thyroid nodules.
The third group (n = 18)
All cases were follicular patterned lesions lacking PTC-N fea-
tures (8 cases were diagnosed follicular adenoma, 6 cases were
Hashimoto thyroiditis and 4 cases were hyperplastic nodules).
This group was considered a control group of benign thyroid
lesions.
Immunohistochemistry
Representative formalin-ﬁxed, parafﬁn embedded routinely
processed, tissue sections from each specimen were stained
with 1:100 a mouse monoclonal CK19 antibody (clone A53-
B/A2.26, Lab vision, USA). Brieﬂy, tissue sections were
deparafﬁnized and rehydrated, antigens were retrieved by
incubating sections in sodium citrate buffer (pH 6.0) in an
Figure 2 Diagnostic nuclear features of WDT-UMP either
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reactions by endogenous hydrogen peroxidase, sections were
incubated at 40 C with CK19 for an hour. Visualization of
staining was conducted using streptavidin–biotin; ABC stain-
ing kit (Catalog # TA-015-HP, Lab-Vision Corporation
Fremont, USA), according to manufacturer’s instructions.
Immunohistochemical reactions were developed with 3,3-
diaminobenzidine; chromogen peroxidase substrate (DAB).
Counterstaining of tissue sections was done using Myer’s
Hematoxylin and mounted using DPX and cover slipped.
Both positive and negative controls were consistently immu-
noreactive and lacking reactivity respectively. This conﬁrms
the validity of the staining results.
Immunohistochemical evaluation
Evaluation included the proportion of reactive cells within the
lesion (the percentage) as well as the staining intensity and its
distribution pattern. The proportion score described the
estimated fraction of positively stained cells (0; no cytoplasmic
staining in any tumor cell, 1+; cytoplasmic staining in less
than 5% tumor cells, 2+; cytoplasmic staining in 5–50%
tumor cells, 3+; cytoplasmic staining in 50–95% tumor cells,
4+; cytoplasmic staining in more than 95% tumor cells) [7].
The intensity score described the staining intensity (0; no
staining, 1+; weak, 2+; moderate, 3+; strong). The dis-
tribution of immunoreactive cells was classiﬁed as diffuse
(when most of cells were stained by CK19) or focal (when
some portion of the tissue presented clusters of stained cells
while other proportions did not) [8].diffuse equivocal PTC-Ns (A and B) or focal unequivocal PTC-
Ns (C and D). Thin incomplete nuclear grooves (black arrows),
nuclear clearing (Red arrow), enlarged ovoid nuclei, mild to
moderate nuclear crowdness and nuclear pleomorphism (HE;
·200, ·400, ·400, ·400, original).Statistical analysis
Statistical package for social sciences (SPSS), version 22 IBM-
Chicago, USA (2013) was used for statistical data analysis.
Pair-wise comparisons were done between groups with down-
ward adjustment of alpha, p-value was considered signiﬁcant if
<0.05 and highly signiﬁcant when <0.001.
Results
The current study compared the histopathological features and
the pattern of immuno-histochemical expression of CK19
among three groups of thyroid lesions; the WDT-UMP, the
malignant and the benign.
All WDT-UMPs (18/18) were follicular patterned nodules
with no vascular or capsular invasion. Nine cases of WDT-
UMPs showed diffuse equivocal (not well developed) PTC-N
type changes (Fig. 2A and B). The other 9 cases showed focal
unequivocal (obvious nuclear features were found in only part
of tumor) (Fig. 2C and D). PTC-N type changes were
diffusely found in all cases of the 2nd group (6 FVPC and
18 classic PTC) (Fig. 3).
According to Chan and Lloyd et al., literatures, the
histomorphological features of malignancy in thyroid- includ-
ing the PTC-N changes – were categorized into major and
minor criteria. We compared these features between WDT-
UMP and both malignant and benign groups (Table 1). The
features were ordered in a descending way according to their
importance in diagnosis [9,10].Major criteria
(1) The nuclear pseudo inclusions (the nuclear invagination,
deﬁned as a deﬁnite inclusion with sharp borders) could
not be found in any cases of WDT-UMP (0/18) (Fig. 2),
detected in 83% (20/24) of PTC cases (2nd group)
(Fig. 3C and D) and were absent in the 3rd group
(benign lesions).
(2) 2-The nuclear groove: sixteen out of eighteen (89%) cases
of WDT-UMPs showed faintly visible, thin and incom-
plete nuclear groove (Fig. 2B and D). This was oppo-
site to the PTC group (2nd group), 24/24 cases showed
frequent thick complete nuclear groove, which was run-
ning across the long axis of the nucleus (complete). The
third group (18/18) was lacking this nuclear feature.
(3) Nuclear clearing was detectable in 100% (18/18) of
WDT-UMP cases (Fig. 2D) and in all cases (24/24) of
the 2nd group (Fig. 3) and occasionally seen in the 3rd
group (5/18).
(4) Nuclear shape: ovoid nuclei were detected in all WDT-
UMPs (18/18) (Fig. 2C) and PTC cases (2nd group,
24/24) and it was occasionally seen in the 3rd group
(2/18) (Fig. 4).
Figure 3 Classic PTC; true papillae (A), strong diffuse expression of CK19 (B), obvious PTC-Ns; nuclear clearing, pseudoinclusion
(black arrow), enlarged ovoid nuclei, marked pleomorphism and overlapping (C and D) (HE; ·200, ·400, ·400-CK19; ·200, original).
Table 1 The major and minor diagnostic criteria in the different groups:
Studied groups WDT-UMP
N= 18(%)
Malignant group N= 24(%) Benign group N= 18(%) Chi-Square P value
Major criteria*
1. Nuclear pseudoinclusion 0(0) 20(83) 0(0) <0.0001
2. Nuclear groove 16(89) 24(100) 0(0) <0.0001
3. Nuclear clearing 18(100) 24(100) 5(28) <0.0001
4. Ovoid nuclei 18(100) 24(100) 2(11) <0.0001
5. Nuclear crowdedness
Moderate 12(66.7) 1(4.2) 2(11) <0.0001
Severe 6(33.3) 23(95.8) 0(0)
6. Nuclear enlargement 17(94.4) 23(95.8) 2(11) <0.0001
7. Nuclear pleomorphism
Mild 9(50) 0(0) 2(11)
Moderate 9(50) 0(0) 0(0) <0.0001
Severe 0(0) 24(100) 0(0)
Minor criteria
1. Distorted follicles 14(78) 24(100) 14(78) 0.09
2. Papillae 2(11) 20(83) 5(28) <0.0001
3. Necrosis 10(55.5) 20(83) 4(22) <0.0001
4. Dense colloid 18(100) 24(100) 16(89) 0.166
5. Fibrosis/sclerosis 12(66.6) 23(96) 9(50) 0.006
* Ranked in descending order according to the importance. [9,10].
62 F.E.-Z.S.E.-D. Yassin(5) Nuclear crowdness and overlapping were moderate to sev-
ere in WDT-UMPs (18/18) (Fig. 2D), while all cases of
PTC (24/24) showed a severe degree of nuclear crowd-
ness and overlapping except one case which showed a
moderate degree (Fig. 3D). Two case of the 3rd group
showed mild to moderate degrees of crowdness (Fig. 4).
(6) Nuclear enlargement: there is a nuclear enlargement in
17/18 of WDT-UMPs in comparison to adjacent nucleiof follicular cells and small nuclei of the adenoma.
Nuclei of PTC showed a marked nuclear enlargement
(23/24) (Fig. 4).
(7) Nuclear pleomorphism: There are mild to moderate
degrees of nuclear pleomorphism in all WDT UMPs
(18/18) and a marked degree in PTC (23/24) cases.
Very mild degree of nuclear pleomorphism could be seen
in the benign group (2/18) (Fig. 4).
Figure 4 Diagnostic features of WDT-UMP versus adenoma and follicular variant of PTC (A, C and E), moderate multifocal expression
of CK 19 in WDT-UMP (D) in comparison to negative expression in adenoma (B) and strong diffuse staining in follicular variant of PTC
(F) (HE; ·400, ·400, ·400-CK19; ·200, ·400, ·200, original).
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previous 7 nuclear features and the diagnosis of WDT-UMP with
p values (<0.0001 for each) (Table 1). The absence of nuclear
pseudoinclusion, presence of characteristic nuclear groove,
nuclear clearing, ovoid nuclei, moderate to severe degrees of
nuclear crowdness, nuclear enlargement and mild to moderate
degrees of nuclear pleomorphism are important features for the
diagnosis of WDT-UMP (Fig. 5).
Minor criteria
(1) Distorted follicles: fourteen out of eighteen (78%) cases
of WDT-UMP showed disturbed follicular pattern com-
pared with 100% of the PTC group and 77.8% in the
benign group (Table 1) (Fig. 4).Figure 5 The major and minor diagnostic criteria of WDT-
UMP.(2) Abortive papillae: were detected in 11% of WDT-UMPs
compared with the true well formed papillae in the clas-
sic variant of papillary carcinoma of the 2nd group (20/
24) (Fig. 3). Three cases of hyperplastic nodules and 2
cases of Hashimoto’s thyroiditis showed abortive papil-
lae (Table 1).
(3) Necrosis: the necrotic areas could be seen in 55.5% (10/
18) of WDT-UMP cases, in 83% (20/24) of the malig-
nant group and in 22% (4/18) of the benign group
(Table 1).
(4) Dense colloids: were seen in 100% cases of WDT-UMP
compared with similar percent in the malignant group
and 88.9% in the benign group (Table 1).
(5) Fibrosis/sclerosis: could be seen in 66.6% (12/18) of
WDT-UMPs with a higher percent (96%) (23/24) being
detected in the malignant group and a lower percent
(50%) (9/18) in the benign group (Table 1).
The presence of papillae (either true or abortive)
(p < 0.0001), necrosis (p < 0.0001) and ﬁbrosis/sclerosis
(p = 0.006) could be found in WDT-UMPs with the steady
increase toward the PTC group (Table 1 and Fig. 5).Immunohistochemical features of CK19
The staining pattern was predominantly pancytoplasmic with
membranous accentuation, the immunoreactivity of CK19
was explained according to the applied proportion and inten-
sity scores (Table 2).
The ﬁrst group (WDT-UMP, n = 18)
Nine cases out of 18 (50%) of WDT-UMPs showed strong
CK19 staining with a proportion score 2+ and the other
50% (9/18 cases) expressed a moderate staining with a
Table 2 Comparison between the studied groups as regards CK 19 expression.
Studied groups Benign group N= 18(%) WDT-UMPs N= 18(%) Malignant N= 24(%) Kruskal–Wallis test P value
Proportion score of CK 19
0 12(66.7) 0(0) 0(0) <0.0001
1+ 6(33.3) 0(0) 0(0)
2+ 0(0) 9(50) 0(0)
3+ 0(0) 9(50) 3(12.5)
4+ 0(0) 0(0) 21(87.5)
Median* 0 70 98
Intensity score of CK 19 expression
0 12(66.7) 0(0) 0(0) <0.0001
1+ 4(22.2) 0(0) 0(0)
2+ 2(11) 9(50) 3(12.5)
3+ 0(0) 9(50) 21(87.5)
Median** 0 2.5 3
* Median of proportion score: Benign = 0 (nil expression), WDT-UMP= 70% (score 3), malignant group = 98% (score 4).
** Median of intensity score: Benign = 0 (nil expression), WDT-UMP= 2.5 (moderate to strong), malignant group = 3 (strong).
Figure 6 WDT-UMP (A) showed intense expression of CK19 in
areas with atypical nuclear features more than the surroundings (B
and C) (HE; ·40-CK19; ·100, ·200, original).
64 F.E.-Z.S.E.-D. Yassinproportion score 3+, as shown in (Fig 4D), the adjacent
normal thyroid follicles showed negative staining of CK19.
The second group (papillary thyroid carcinoma, n = 24)
The classic PTC (18/18) cases showed a strong expression of
CK19 with a proportion score 4+, (Fig. 3B), the follicular
variant (6/6) cases showed moderate to strong staining with
proportion scores ranging between 3+ and 4+, (Fig. 4F).
The third group (benign thyroid lesions, n = 18)
The expression of CK19 in adenoma and hyperplastic nodules
were negative except in 2 cases of adenoma which showed a
weak focal positivity (Fig. 4B), Hashimoto’s thyroiditis (4/6)
showed weak to moderate immunostaining with a proportion
score 1+.
CK 19 immunostaining of WDT-UMP showed an inter-
mediate expression proﬁle; higher than adenoma and less than
PTC with P value (<0.0001) (Table 2).
An interesting phenomenon was noticed within WDT-
UMPs; areas with obvious PTC nuclear features showed more
intense expression of CK19 than the surrounding areas of less
atypical nuclear features. This gave an impression of a nodule
(with more atypia) within the nodule (WDT-UMP) (Fig. 6). It
is similar to what happens in dysplastic changes of the liver.
Discussion
The current study compared the histopathological criteria of
WDT-UMP lesions versus benign and malignant lesions.
More light was also shed on the pattern of immunohistochemi-
cal expression of CK19; a proven helpful distinguishing
marker between the three lesion types.
The term ‘‘well differentiated tumor of uncertain malignant
potential or WDT-UMP’’ was proposed for follicular
patterned lesions of the thyroid that cannot be readily diag-
nosed as benign or malignant because of questionable nuclear
changes and absent capsular or vascular invasion [1]. The mainreason behind this proposal was to avoid extensive treatment
(total thyroidectomy followed by radioactive iodine) of thyroid
tumors which clinically behave in a benign fashion and carry
excellent prognosis [11].
Although no single morphological feature is pathog-
nomonic of malignancy in thyroid lesions; a constellation of
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PTC. Chan in his literature, categorized the histomorphologi-
cal features of malignancy into; major and minor (subsidiary)
criteria [9].
The current study emphasized on both major and minor
criteria of WDT-UMPs. On the top of the list of major criteria
is the nuclear pseudoinclusions which is considered as a major
exclusive feature, it was found only in PTC cases (83%) and
absent in both the WDT-UMPs (0/18) and benign group (0/
18). Its presence is a diagnostic clue for malignancy. Our
results were close to what was mentioned by Liu et al., as they
reported the absence of nuclear pseudoinclusion in all WDT-
UMPs (30 cases) opposite to 3–8% were observed in follicular
variant of PTC [3]. Furthermore, Lloyd et al., in a survey study
for diagnostic criteria of malignancy, documented the
cytoplasmic pseudoinclusion as one of the three most impor-
tant diagnostic features of malignancy (the others; abundant
nuclear grooves and ground glass nuclei) [10].
The second most important major criteria is the nuclear
groove as reported by Nishigami and his colleagues in a
cyto-morphological study, they clariﬁed the incidence of
nuclear grooves in broad spectral thyroid lesions; they did
not ﬁnd the nuclear grooves in adenomatous goiter or follicu-
lar adenoma while they found the incidence of nuclear groove
increased gradually from WDT-UMPs (4.5%) to PTC (6.5%).
They added that the difference between the nuclear grooves of
WDT-UMP which were rare, thin and faintly visible while that
of PTC were dense, running across the long axis of the nucleus
[12]. These results were conﬁrmed by the current study, as we
did not found any grooves in the benign group (adenoma and
goiter) while we found frequent complete grooves in all cases
of the malignant group (PTC; 100%). Furthermore, in
WDT- UMPs; 16 out of 18 cases (89%) showed characteristic
incomplete thin groove with irregular distribution.
The nuclear clearing or ground glass nuclei- as a third
feature- was observed in 100% of WDT-UMPs and 100% of
malignant cases in our study, the difference was clear in
comparison to the hyper chromatic nuclei of adenoma.
These ﬁgures came in accordance with Liu and his colleagues,
as they reported nuclear clearing in 30/30 cases of WDT-
UMPs [3]. Other supportive studies ranked the nuclear clear-
ing as one of the most important diagnostic features of thyroid
malignancy among experts [9,13].
However, we could not consider the previous feature as an
isolated reliable criterion for the diagnosis of WDT-UMP,
because we recognized it in 28% of the benign group
(Hashimoto thyroiditis and hyperplastic nodule). So it should
be incorporated with other major features. Rosai and his col-
leagues reported the vesicular nuclei in wide range of benign
and malignant thyroid disorders and they considered it of no
diagnostic signiﬁcance by itself [14].
Nishigami and his colleagues, in the morphometric study of
spectral thyroid lesions clariﬁed the degree of nuclear circular-
ity of WDT-UMP; it was found to be statistically smaller than
that of PTC. This ﬁnding was detected roughly in our study,
whereas the ovoid nuclei were apparent in 100% of all cases
of WDT- UMPs and in 100% of the malignant group while
the nuclei of adenoma were more circular [12].
Both Chan and Elsheikh and their colleagues reported the
ovoid nuclei on the top of the most important list of PTC-N
features [9,13].In the current study; the epithelium of thyroid follicles in
WDT-UMPs still had polarity but the cells were crowded
(moderate to severe degrees). This was opposite to the PTC
group in which the polarity was lost and the nuclei were over-
lapped (more severe crowdness), and the benign group missed
this feature. Liu and his colleagues, found the same feature in
thirty cases of WDT-UMPs; preservation of the polarity with
nuclear crowdness but without overlapping which was seen in
frank malignancy [3]. Another supportive study by Chan,
reported the nuclear crowdness as the second most important
criteria of nuclear atypia [9].
Liu and his colleagues reported the nuclear size of WDT-
UMP was 2–4 times that of normal thyroid follicular cells.
This came in agreement with our results where we found
variable degrees of nuclear enlargement in most cases of
WDT-UMPs (94.4%) and PTC (95.8%) in comparison to
11% of the adenoma group [3].
The last major criterion is the nuclear pleomorphism; all
cases of WDT-UMPs showed mild to moderate degrees while
95.8% of PTC revealed a marked degree of nuclear pleomor-
phism. Very mild degree of nuclear pleomorphism could be
seen in 4.2% of the benign group. Our results were supported
by Elsheikh et al., where they detected this feature clearly in
WDT-UMPs [13].
The current study considered the presence of characteristic
nuclear groove, nuclear clearing, ovoid nuclei, moderate to severe
degrees of nuclear crowdness, nuclear enlargement and mild to
moderate degrees of nuclear pleomorphism are important reli-
able features of WDT-UMP’ diagnosis.
Chan’ study considered the irregularly shaped follicles,
presence of sclerosis, dense colloid, necrosis and abortive
papillae as minor (subsidiary) criteria, especially if one or more
features of the major ones were lacking [9]. We could detect the
minor criteria in variable percent in study groups, however, we
could not consider them as separate dependable features for
diagnosis of WDT-UMP.
In the current study, the necrotic areas were focally seen in
the surrounding stroma or within the thyroid nodules. They
attributed to several causes; processing artifact at the sites of
previous ﬁne needle aspiration cytology or biopsy, secondary
to cystic degeneration [9,10], or due to infarction.
We could see focal areas of ﬁbrosis/sclerosis in 66.6% of
WDT-UMPs. They were recognized in proximity to lympho-
cytic thyroiditis or hyperplastic nodules. So we considered
them an associated condition rather than pattern of growth
for WDT-UMP. Hoffmann and his colleagues conﬁrmed our
ﬁndings [15].
Additional evidence came from Elsheikh and his colleagues’
study; they listed the distorted follicular architectures, ﬁbrosis,
dense colloid and abortive follicles as secondary features for
the diagnosis of malignancy in follicular lesions of the thyroid
as cited by experts [13].
On the basis of the criteria proposed by the Chernobyl
Pathologist Group [1], we developed an intimate description of
nuclear changes of WDT-UMP including; the absence of nuclear
pseudoinclusion, presence of characteristic nuclear groove
(89%), nuclear clearing (100%), ovoid nuclei (100%), nuclear
enlargement (94.4%), nuclear crowdness (moderate–severe)
and nuclear pleomorphism (mild to moderate), either with focal
and well developed or diffuse and equivocal distribution. So the
nucleus of WDT-UMP has more atypia than follicular adenoma
66 F.E.-Z.S.E.-D. Yassinbut less than PTC nucleus. Moreover, minor criteria were con-
sidered as alarming subsidiary features (Fig. 5).
We used CK19 as a proven useful marker to conﬁrm the
diagnosis especially when the cyto-morphological features
were equivocal and did not offer conclusive diagnosis. The dis-
tribution and the intensity of CK 19 staining were very helpful
for accurate interpretation and differential diagnosis [16,17].
Cytokeratin 19 displayed several patterns of immunoreactiv-
ity in the current study;
The classic PTC (18/18) showed strong immunoreactivity of
CK19 with distribution more than 95% of tumor cells. While
50% of the cases of follicular variant showed strong staining
with distribution more than 50% and the other 50% of cases
showed moderate intensity with distribution more than 95%
of the tumor. Several authors agreed with us and demonstrated
strong, diffuse CK19 immunoreactivity in 80–100% of PTC
cases [16,17], while Bukhari and his colleagues’ study reported
a larger number of cases (60 cases of follicular variant of papil-
lary carcinoma) expressed 4+(>95% cells were CK19 posi-
tive) [18]. The negative staining of CK19 was considered
strong evidence against diagnosis PTC [19].
Our study demonstrated CK19 immunoreactivity in 100%
of WDT-UMPs; 50% of cases showed moderate staining of
CK19 with distribution more than 50% up to 95% of the
tumor. The other 50% of WDT-UMPs showed strong
immunoreactivity in 50% of the follicular lesion. Thus, we
considered the pattern of immunoreactivity of CK19 in
WDT-UMPs varied from moderate diffuse to strong multifo-
cal immunostaining.
Although a few immunohistochemical studies on WDT-
UMPs were found in the literature, their results were close to
ours. Bukhari & his colleagues and Barut et al. [18,20] demon-
strated a signiﬁcant positivity (strong diffuse) of CK19 in
WDT-UMPs; they found wide proportions of the stained cells
among 35 cases (ranged from 5% to 95%). However, a lower
expression of CK19 was reported by Scognamiglio [21] and by
Hoffmann et al. [15]; they recorded that 63–64% of WDT-
UMPs expressed CK19.
Many additional studies supported the previous immuno-
histochemical proﬁle of WDT-UMP and concluded that these
lesions might be biologically borderline lesions which represent
an early phase of carcinogenesis and precursor lesions of PTC
[22–24].
Our study showed a weak focal positivity of CK19 in 2
cases of adenoma and 4 cases of Hashimoto thyroiditis.
These ﬁndings came in agreement with others [18,25–27] who
reported nil or focal positivity of CK19 in follicular adenomas.
The follicular cell expression of CK19 within lymphocytic
thyroiditis could be explained by the presence of reactive
follicular epithelium around areas of degeneration especially
at the sites of previous needle biopsy [25].
In our study, the immunostaining proﬁle of CK19 in WDT-
UMPs ranged from moderate to strong staining with a propor-
tion score range of 50–95% which is higher than adenoma and
less than carcinomas. This came in agreement with
Scognamiglio and his colleagues [13] who performed immuno-
histochemical studies using a panel of four antibodies (HBME-
1, GAL3, CK19 and CITED1). They reported 5/11 cases of
WDT-UMPs with an intermediate expression proﬁles between
PTC and FA.
In the current study, areas with obvious PTC nuclear fea-
tures that showed more intense expression of CK19 than thesurrounding of less atypical nuclear features in WDT-UMPs,
giving an impression of a nodule (with more atypia) inside
the nodule (WDT-UMP). The association between PTC
nuclear features distribution and the immunoreactivity pattern
of CK19 could be explained from the molecular point of view.
This is because RET/PTC rearrangements have been restricted
to the focal areas of unequivocal nuclear features of PTC,
representing an early development of PTC in a pre-existing
benign lesion [28].
Although the molecular characterization of WDT-UMP is
still under great observer variability, it had distinct molecular
features compared to PTC and benign thyroid lesions [3].
Some authors considered the WDT-UMP as an early phase
of carcinogenesis (pre-cancerous), borderline and a very low
grade malignancy [22].
We concluded that WDT-UMP is an intermediate lesion;
differs from adenoma and benign lesions of the thyroid and
shares the PTC to certain extent. However, a constellation of
both histomorphological features and immunohistochemical
CK19 ﬁndings can provide reliable features for the diagnosis
of WDT-UMP.
More histopathological and molecular studies on bigger
number of specimens with long term follow up data are
recommended for better understanding of the neoplastic
nature of the WDT-UMP thyroid lesions.
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